000155694 001__ 155694
000155694 005__ 20240403115639.0
000155694 0247_ $$2doi$$a10.3389/fneur.2021.684523
000155694 0247_ $$2pmid$$apmid:34276540
000155694 0247_ $$2pmc$$apmc:PMC8282895
000155694 0247_ $$2altmetric$$aaltmetric:108542659
000155694 037__ $$aDZNE-2021-00862
000155694 041__ $$aEnglish
000155694 082__ $$a610
000155694 1001_ $$aWillroider, Marie$$b0
000155694 245__ $$aSuperiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [ 18 F]PI-2620.
000155694 260__ $$aLausanne$$bFrontiers Research Foundation$$c2021
000155694 3367_ $$2DRIVER$$aarticle
000155694 3367_ $$2DataCite$$aOutput Types/Journal article
000155694 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712135986_27006
000155694 3367_ $$2BibTeX$$aARTICLE
000155694 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155694 3367_ $$00$$2EndNote$$aJournal Article
000155694 520__ $$aObjectives: Autoradiography on brain tissue is used to validate binding targets of newly discovered radiotracers. The purpose of this study was to correlate quantification of autoradiography signal using the novel next-generation tau positron emission tomography (PET) radiotracer [18F]PI-2620 with immunohistochemically determined tau-protein load in both formalin-fixed paraffin-embedded (FFPE) and frozen tissue samples of patients with Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP). Methods: We applied [18F]PI-2620 autoradiography to postmortem cortical brain samples of six patients with AD, five patients with PSP and five healthy controls, respectively. Binding intensity was compared between both tissue types and different disease entities. Autoradiography signal quantification (CWMR = cortex to white matter ratio) was correlated with the immunohistochemically assessed tau load (AT8-staining, %-area) for FFPE and frozen tissue samples in the different disease entities. Results: In AD tissue, relative cortical tracer binding was higher in frozen samples when compared to FFPE samples (CWMRfrozen vs. CWMRFFPE: 2.5-fold, p < 0.001), whereas the opposite was observed in PSP tissue (CWMRfrozen vs. CWMRFFPE: 0.8-fold, p = 0.004). In FFPE samples, [18F]PI-2620 autoradiography tracer binding and immunohistochemical tau load correlated significantly for both PSP (R = 0.641, p < 0.001) and AD tissue (R = 0.435, p = 0.016), indicating a high agreement of relative tracer binding with underlying pathology. In frozen tissue, the correlation between autoradiography and immunohistochemistry was only present in AD (R = 0.417, p = 0.014) but not in PSP tissue (R = -0.115, p = n.s.). Conclusion: Our head-to-head comparison indicates that FFPE samples show superiority over frozen samples for autoradiography assessment of PSP tau pathology by [18F]PI-2620. The [18F]PI-2620 autoradiography signal in FFPE samples reflects AT8 positive tau in samples of both PSP and AD patients.
000155694 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155694 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000155694 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155694 650_7 $$2Other$$aPI-2620
000155694 650_7 $$2Other$$aautoradiography
000155694 650_7 $$2Other$$aimmunohistochemistry
000155694 650_7 $$2Other$$aprogressive supranuclear palsy
000155694 650_7 $$2Other$$atau
000155694 7001_ $$aRoeber, Sigrun$$b1
000155694 7001_ $$aHorn, Anja K E$$b2
000155694 7001_ $$0P:(DE-2719)2811333$$aArzberger, Thomas$$b3$$udzne
000155694 7001_ $$0P:(DE-2719)9001444$$aScheifele, Heinrich Maximilian$$b4$$udzne
000155694 7001_ $$0P:(DE-2719)2811600$$aRespondek, Gesine$$b5$$udzne
000155694 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b6$$udzne
000155694 7001_ $$aBarthel, Henryk$$b7
000155694 7001_ $$aPatt, Marianne$$b8
000155694 7001_ $$aMishchenko, Olena$$b9
000155694 7001_ $$aSchildan, Andreas$$b10
000155694 7001_ $$aMueller, André$$b11
000155694 7001_ $$aKoglin, Norman$$b12
000155694 7001_ $$aStephens, Andrew$$b13
000155694 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b14$$udzne
000155694 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b15$$udzne
000155694 7001_ $$aBartenstein, Peter$$b16
000155694 7001_ $$0P:(DE-2719)2810441$$aHerms, Jochen$$b17$$udzne
000155694 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b18$$udzne
000155694 7001_ $$aBeyer, Leonie$$b19
000155694 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2021.684523$$gVol. 12, p. 684523$$p684523$$tFrontiers in neurology$$v12$$x1664-2295$$y2021
000155694 8564_ $$uhttps://pub.dzne.de/record/155694/files/DZNE-2021-00862.pdf$$yOpenAccess
000155694 8564_ $$uhttps://pub.dzne.de/record/155694/files/DZNE-2021-00862.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155694 909CO $$ooai:pub.dzne.de:155694$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000155694 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811333$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000155694 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001444$$aExternal Institute$$b4$$kExtern
000155694 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811600$$aExternal Institute$$b5$$kExtern
000155694 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b6$$kExtern
000155694 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000155694 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000155694 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810441$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000155694 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001539$$aExternal Institute$$b18$$kExtern
000155694 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155694 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000155694 9130_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000155694 9130_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x1
000155694 9141_ $$y2021
000155694 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000155694 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-28
000155694 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000155694 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2021$$d2022-11-18
000155694 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:11:28Z
000155694 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000155694 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:11:28Z
000155694 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000155694 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000155694 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-18
000155694 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155694 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:11:28Z
000155694 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000155694 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000155694 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-28
000155694 9201_ $$0I:(DE-2719)1140013$$kNeuropathology / Brainbank$$lNeuropathology / Brainbank$$x0
000155694 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000155694 9201_ $$0I:(DE-2719)1110001$$kAG Herms$$lTranslational Brain Research$$x2
000155694 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x3
000155694 980__ $$ajournal
000155694 980__ $$aVDB
000155694 980__ $$aUNRESTRICTED
000155694 980__ $$aI:(DE-2719)1140013
000155694 980__ $$aI:(DE-2719)1111015
000155694 980__ $$aI:(DE-2719)1110001
000155694 980__ $$aI:(DE-2719)1111016
000155694 9801_ $$aFullTexts